New PhD student at Rücklab: Oskar Flygare


Hi! My name is Oskar Flygare and I’m the latest addition to the group of PhD students at Rücklab. I have been working in the group for a year and am now a registered doctoral student with Christian Rück as main supervisor. Co-supervisors are David Mataix-Cols and Erik Andersson.

Oskar Flygare 2

Photo: Martin Hammar

The focus of my PhD thesis is the psychological treatment of OCD

Lina Lundström and I are the project managers of a randomised controlled trial that compares two types of internet-delivered cognitive behavioural therapy (ICBT) with face-to-face cognitive behavioural therapy for adults with OCD. The three treatments are:

  • Individual face-to-face CBT
  • Therapist-guided ICBT
  • Self-guided ICBT

120 individuals will be randomised to receive one of the treatments, i.e. 40 patients in each treatment arm. Treatment lasts for 14 weeks. We are recruiting participants and you can register here.

Our main goal is to evaluate the treatments on how well they provide symptom relief. In addition to this, I will also perform cost-effectiveness analyses on the three treatments, i.e. evaluate the benefits in relation to costs. My study plan also contains research on predictors and moderators of treatment outcome.

When I’m not doing a deep-dive in obscure research, I enjoy playing and listening to music. I have been playing the saxophone for 15 years and wanted to become a professional musician when I was a teenager. I came to my senses after three years of intense music studies in high school and switched to psychology.

Please get in touch if you want to exchange ideas or talk about interesting research! I am always curious, sometimes thoughtful and never indifferent.

Visit from Blake Dear of eCentreClinic, Australia

Dr. Blake F. Dear, Co-Director of the eCentreClinic in Australia, recently visited Karolinska Institutet to partake in the dissertation of Marianne Bonnert. While in Sweden, he also gave a talk on recent updates from the Australian eCentreClinic. They develop internet-delivered psychological treatments for common mental health and physical health conditions.


Continue reading

New meta-analysis in JAMA Psychiatry: Does d-cycoserine add to CBT?

D-cycloserine (DCS) is a partial NMDA agonist that facilitates fear extinction in animals and reduces return of fear when given before  extinction training. Despite several initial trials showing promising results in humans with anxiety disorders larger trials conducted within the past 5 years have produced mixed results. Our large trial in obsessive-compulsive disorder22 found no general effect of DCS but a significant interaction effect between DCS and antidepressant medication in a post hoc analysis;  antidepressants impaired treatment response in patients randomized to DCS but not in patients randomized to placebo.

We collected Individual participant data for 21 of 22 DCS trials, representing 1047 of 1073 eligible participants. When controlling for antidepressant use, participants receiving DCS showed greater improvement from pretreatment to posttreatment (mean difference, −3.62; 95% CI, −0.81 to −6.43; P = .01; d = −0.25) but not from pretreatment to midtreatment (mean difference, −1.66; 95% CI, −1.60 to 4.92; P = .32; d = −0.14) or from pretreatment to follow-up (mean difference, −2.98, 95% CI, −0.03 to 5.99; P = .05; d = −0.19). Only 1 significant moderator emerged: year of publication. Specifically, the more recent the study, the smaller the difference between DCS and placebo for pretreatment to follow-up improvement (b = 4.02; 95% CI, 0.59-7.45; P = .02, d = 0.26).

Conclusion: D-cycloserine is associated with a small augmentation effect on exposure-based therapy. The small size of the effect makes the clinical usefulness of DCS doubtful.


Mataix-Cols D, Fernández de la Cruz L, Monzani B, Rosenfield D, Andersson E, Pérez-Vigil A, Frumento P, de Kleine RA, Difede J, Dunlop BW, Farrell LJ, Geller D, Gerardi M, Guastella AJ, Hofmann SG, Hendriks G, Kushner MG, Lee FS, Lenze EJ, Levinson CA, McConnell H, Otto MW, Plag J, Pollack MH, Ressler KJ, Rodebaugh TL, Rothbaum BO, Scheeringa MS, Siewert-Siegmund A, Smits JAJ, Storch EA, Ströhle A, Tart CD, Tolin DF, van Minnen A, Waters AM, Weems CF, Wilhelm S, Wyka K, Davis M, Rück C, for the DCS Anxiety Consortium. D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress DisordersA Systematic Review and Meta-analysisJAMA Psychiatry. Published online January 25, 2017. doi:10.1001/jamapsychiatry.2016.3955



Rücklab retreat 2017


From left to right: Josef Isung, Diana Radu Djurfeldt, Gustaf Brander, Volen Ivanov, James Crowley, Christian Rück, Lina Lundström, Oskar Flygare, Andrew Gentile, Evelyn Andersson, Julia Boberg, Mia Asplund and Jesper Enander.

It’s officially 2017, and the members of our group took to Yasuragi spa & bath outside Stockholm for this year’s retreat! Although some were more devoted to the Yasuragi-outfits than others (see above), everyone participated in the different activities with enthusiasm.

Continue reading

Our 2016 in review

While the world around us may have had a perplexing year, we have in fact had a great year  when it comes to research.

Here is a review of some of what has happened in our group:

In our own humble opinion we have published some landmark studies:

A large randomised controlled trial of internet-based CBT for Body Dysmorphic Disorder, showing excellent results, published in the BMJ with Jesper Enander as lead author.

The largest study so far looking at risk factors around birth in Obsessive-Compulsive Disorder (OCD), published in JAMA Psychiatry with Gustaf Brander as lead and David Mataix-Cols as senior author. This study to me also shows the power of Swedish national registries.

The largest study so far looking at suicide in OCD and finding a much higher suicide rate than expected. Lead author is the brilliant Lorena Fernandez de la Cruz and this master piece out of the Mataix-Cols kitchen was published in Molecular Psychiatry. A similar study on tic disorders was also published in Biological Psychiatry.

Fabian Lenhard pioneered the first randomised study looking at ICBT for adolescents our neighbouring research group of Eva Serlachius. It was just published in JAACAP.

What else did we publish in 2016? Check

Genetics: major study started and harvest time for some

We have started a new big study trying to understand the complex genetical architecture of OCD and related disorders. You can read more about the study here. Good news is that data collection is going well (=lots of DNA) and that we in this year have built a lot of infrastructure to ensure a bright future for the project.

We are collecting samples at 8 centers in Sweden and this study is part of a larger Nordic effort called, yes, NORDiC! Read all about NORDiC here:


We have DNA from about 2500 individuals who have undergone internet-CBT for other anxiety disorders and depression. It is now harvest time for some of that, data is being analysed at different sites in Europe with Evelyn Andersson as the coordinating PhD student.

New people

Oskar Flygare has secured a CSTP-grant and will start a PhD early next year in tight collaboration with Lina Lundström.

Annelie Porsborn, Julia Boberg and Susanne Alm are our new front-line soldiers, all employed in the OCD genetics project.

Long-Long Chen and Mia Asplund are both hang-arounds likely to go into a PhD next year on poo bacteria, Deep Brain Stimulation and skin-picking and hair-pulling. What a mix!


A special shout out to Volen Ivanov who has tirelessly educated hundreds of people in the social services on Hoarding Disorder!

We wish you all a great 2017! Thank YOU to all our collaborators, research subjects, readers and funders!

End of a trial

Last week we had the honor of being visited by a lab alumni, Erik Andersson. It was time to close and archive our trial where we tested the efficacy of d-cycloserine as an add on to CBT for OCD. You can read the results of that trial here in Jama Psychiatry. Now all the follow-ups are done and it was time to close the trial, send the end-of-trial forms to the Swedish Medical Products agency and to return the drugs to the pharmacy.

It was really a trip down memory lane, remembering how we got APL Pharmaceuticals to produce both the drug and placebo, the massive workload for all approvals and the task of actually get such a big trial done. Broke the bank and got us a few gray hairs. Good news is that the treatment with internet-based CBT in the trial was very helpful for the participants.


Erik saying a a few last words to the capsule before going to destruction.


Still smiling after all these years.